 Abstract of study results submitted by the third-party investigators to December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA ACCESSWIRE July 14, 2021 Jaguar Health, Inc. NASDAQ:JAGX today announced that the third-party, investigator-initiated Phase 2 HALT-D study evaluating the effectiveness of Mytesi crofelemer for symptomatic relief of diarrhea in HER2 positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab, and docetaxel or paclitaxel or trastuzumab, pertuzumab, carboplatin, and docetaxel has been completed. The investigators of the study, which was sponsored by Georgetown University and funded by Genentech, a member of the Roche Group, have submitted an abstract of the results to the San Antonio Breast Cancer Symposium for consideration for presentation at its December 7-10, 2021 event. 